Clinical Trials Logo

Filter by:
NCT ID: NCT00568750 Completed - Clinical trials for Gastrointestinal Stromal Tumor

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Start date: January 22, 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works as first-line therapy in treating patients with gastrointestinal stromal tumors.

NCT ID: NCT00568048 Completed - Melanoma (Skin) Clinical Trials

Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Start date: December 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving temozolomide together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving temozolomide together with bevacizumab works in treating patients with stage IV melanoma that cannot be removed by surgery.

NCT ID: NCT00567567 Completed - Clinical trials for Recurrent Neuroblastoma

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Start date: November 5, 2007
Phase: Phase 3
Study type: Interventional

This randomized phase III trial compares two different high-dose chemotherapy regimens followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments before a peripheral blood stem cell transplant helps kill any tumor cells that are in the body and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. High-dose chemotherapy and radiation therapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the high- chemotherapy. It is not yet known which regimen of high-dose chemotherapy is more effective for patients with high-risk neuroblastoma undergoing a peripheral blood stem cell transplant.

NCT ID: NCT00567515 Completed - Atrial Fibrillation Clinical Trials

Safety and Effectiveness of Left Atrial Appendage Occlusion

Start date: September 2007
Phase: Phase 2
Study type: Interventional

This study is to evaluate acute and long-term safety and effectiveness of Left atrial appendage occlusion (LAA)with the AtriCure LAA Occlusion System. This device will be applied in patients with atrial fibrillation (AF), paroxysmal, persistent and permanent, undergoing cardiac surgery with a concomitant Maze/Ablation procedure.

NCT ID: NCT00566657 Completed - Clinical trials for Peripheral Vascular Diseases

Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions

TAMARIS
Start date: November 2007
Phase: Phase 3
Study type: Interventional

Primary objective is to demonstrate the superiority of riferminogene pecaplasmid over placebo in the prevention of major amputation above the ankle of the treated leg or of death from any cause, whichever comes first, in critical limb ischemia (CLI) patients with skin lesions. Secondary objectives are to evaluate: - The efficacy of riferminogene pecaplasmid versus placebo for delaying the time to major amputation; - The efficacy of riferminogene pecaplasmid versus placebo for delaying the time to death; - The safety of riferminogene pecaplasmid in the study population.

NCT ID: NCT00564291 Completed - Macular Edema Clinical Trials

Evaluation of Retinal Structure With High Resolution Optical Coherence Tomography (OCT)

Start date: January 2007
Phase:
Study type: Observational

Comparison of different OCT instruments to assess retinal thickness, correlation to fluorescein angiography, and visual outcome after therapy with anti-VEGF therapy

NCT ID: NCT00564109 Recruiting - Clinical trials for Trauma Patients With Soft Tissue Defects

Are the Pancreatic Serum Proteins Pancreatic Stone Protein (PSP) and Pancreatitis-Associated Protein (PAP) Predictive for the Development of Sepsis? Retrospective Study in Trauma Patients With Soft Tissue Defects.

Start date: August 2005
Phase: N/A
Study type: Observational

Retrospective analysis of PSP- and PAP-serum levels in trauma patients with soft tissue defects and possible correlation with the incidence and onset of infection and sepsis.

NCT ID: NCT00563979 Completed - Clinical trials for Age-Related Maculopathies

Enhancement of Macular Pigment Density by Oral Lutein Supplementation

EMPOLS
Start date: July 2007
Phase: N/A
Study type: Interventional

The primary objective of EMPOLS is an increase in macular pigment density (MPD) and contrast sensitivity (CS) after six months supplementation of oral non-compound ester Lutein 10 mg daily, contained in VitaluxPlus®.

NCT ID: NCT00563940 Completed - Clinical trials for Diabetic Macular Edema

Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema

Start date: March 2007
Phase:
Study type: Observational

Diabetic macular edema is a common complication of ocular diabetes mellitus and can cause blindness. Hypoxygenation of the retina stimulates tissue mediators, especially different subtypes of vascular endothelial growth factor (VEGF). VEGF is responsible for proliferation, extension and increased permeability of the vessels. The aim of our study was to examine the short-term effect of intravitreal bevacizumab (Avastin® 1.25 mg in 0.05 ml) and triamcinolone on visual acuity and central retinal thickness in patients with clinically significant diabetic macular edema (CSME).

NCT ID: NCT00562900 Completed - Cholecystolithiasis Clinical Trials

Robotic Assisted Versus Laparoscopic Cholecystectomy - Outcome and Cost Analyses of a Case-Matched Control Study

Start date: December 2004
Phase: Phase 4
Study type: Interventional

Case matched study on 50 consecutive patients undergoing robotic assisted cholecystectomy (Da Vinci Robot, Intuitive Surgical). These patients are matched 1:1 to 50 patients with conventional laparoscopic cholecystectomy, according to age, gender, ASA score, histology and surgical experience. - Trial with surgical intervention